126 related articles for article (PubMed ID: 12095927)
1. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma.
Giannitrapani L; Cervello M; Soresi M; Notarbartolo M; La Rosa M; Virruso L; D'Alessandro N; Montalto G
Ann N Y Acad Sci; 2002 Jun; 963():46-52. PubMed ID: 12095927
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.
Soresi M; Giannitrapani L; D'Antona F; Florena AM; La Spada E; Terranova A; Cervello M; D'Alessandro N; Montalto G
World J Gastroenterol; 2006 Apr; 12(16):2563-8. PubMed ID: 16688802
[TBL] [Abstract][Full Text] [Related]
3. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
Pignatti P; Ciapponi L; Galle P; Hansen MB; Massa M; Meazza C; Paonessa G; Novick D; Ciliberto G; Martini A; De Benedetti F
Clin Exp Immunol; 2003 Feb; 131(2):355-63. PubMed ID: 12562400
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
[TBL] [Abstract][Full Text] [Related]
6. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Costes V; Liautard J; Picot MC; Robert M; Lequeux N; Brochier J; Baldet P; Rossi JF
J Clin Pathol; 1997 Oct; 50(10):835-40. PubMed ID: 9462266
[TBL] [Abstract][Full Text] [Related]
7. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
8. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-6 receptor enhanced by oncostatin M induces major changes in gene expression profile of human hepatoma cells.
Holub MC; Hegyesi H; Igaz P; Polgár A; Toth S; Falus A
Immunol Lett; 2002 Jun; 82(1-2):79-84. PubMed ID: 12008038
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients.
Vladić A; Horvat G; Vukadin S; Sucić Z; Simaga S
Cytokine; 2002 Oct; 20(2):86-9. PubMed ID: 12445803
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR
Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.
Bagli M; Papassotiropoulos A; Hampel H; Becker K; Jessen F; Bürger K; Ptok U; Rao ML; Möller HJ; Maier W; Heun R
Eur Arch Psychiatry Clin Neurosci; 2003 Feb; 253(1):44-8. PubMed ID: 12664314
[TBL] [Abstract][Full Text] [Related]
16. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.
Gabay C; Silacci P; Genin B; Mentha G; Le Coultre C; Guerne PA
Eur J Immunol; 1995 Aug; 25(8):2378-83. PubMed ID: 7545121
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
